MAMaha Hammam M. A. Al-Shamali

Maha Hammam M. A. Al-Shamali

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Maha Hammam M. A. Al-Shamali has a total of 43 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Association between Multimorbidity and COVID-19 Mortality in Qatar: A Cross-Sectional Study

    by Khalid AbouGalala, Basant Elsayed, Mohamed Elmarasi, Mona Kotob, Reham Taha, Fardous Abbasher, Ahmed Amarah, Mariam El Hamawi, Soha S. Albayat, Jazeel Abdulmajeed, et al.

    This study assessed the association between multimorbidity and mortality from COVID-19 in the Middle East and North Africa region, where such data are scarce. We conducted a cross-sectional study using data of all cases with COVID-19 reported to the Ministry of Public Health of Qatar from March to September 2020. Data on pre-existing comorbidities were collected using a questionnaire and multimorbidity was defined as having at least two comorbidities. Proportions of deaths were compared by comorbidity and multimorbidity status and multivariable logistic regression analyses were carried out. A total of 92,426 participants with a mean age of 37.0 years (SD 11.0) were included. Mortality due to COVID-19 was associated with gastrointestinal diseases (aOR 3.1, 95% CI 1.16–8.30), respiratory diseases (aOR 2.9, 95% CI 1.57–5.26), neurological diseases (aOR 2.6, 95% CI 1.19–5.54), diabetes (aOR 1.8, 95% CI 1.24–2.61), and CVD (aOR 1.5, 95% CI 1.03–2.22). COVID-19 mortality was strongly associated with increasing multimorbidity; one comorbidity (aOR 2.0, 95% CI 1.28–3.12), two comorbidities (aOR 2.8, 95% CI 1.79–4.38), three comorbidities (aOR 6.0, 95% 3.34–10.86) and four or more comorbidities (aOR 4.15, 95% 1.3–12.88). This study demonstrates a strong association between COVID-19 mortality and multimorbidity in Qatar.


  • Open Access

    Dengue Epidemiology in Qatar from 2013–2021: A Retrospective Study

    by Elmoubashar Abd Farag, Shariq Jaffrey, Faisal Daraan, Maha Hammam M. A. Al-Shamali, Fahmi Y. Khan, Peter V. Coyle, Francis Schaffner, Hamad Eid Al-Romaihi, Mohammed Al-Thani, Devendra Bansal

    (1) Background: Qatar does not have any indigenous cases of dengue; however, the influx of immigrants from dengue endemic countries, the environment, and climate suitability for Aedes vector mosquitoes suggest a potential risk for local transmission. In this study, we investigated various demographic factors to determine the epidemiological features of dengue in Qatar. (2) Methods: In the present retrospective study, we reviewed dengue notification data received at the national surveillance system, Ministry of Public Health, Qatar, between January 2013, and December 2021, and we analyzed the incidence of the dengue disease burden to identify factors that could contribute to the dissemination of the disease in Qatar. (3) Results: A total of 166 dengue fever seropositive cases were recorded during the study period in Qatar. The mean incidence was estimated to be 0.7/100,000 population, which increased from 0.7/100,000 in 2013 to 1.5/100,000 in 2019. The majority of the cases were male, between 20–50 years of age and notified during the hot months (June-September). Most of the patients had fever without hemorrhagic manifestations. There were no dengue related deaths during 2013–2021. (4) Conclusion: Dengue fever occurred more frequently among men than women, and its incidence is low among Qatari nationals. The presence of the most efficient vector, Aedes aegypti, in Qatar, if confirmed, poses a risk of local outbreaks. Therefore, regular vector surveillance is needed to assess the distribution, biting habits and abundance of vector mosquito species and the risk for mosquito-borne diseases.


  • Open Access

    Duration of COVID-19 mRNA Vaccine Effectiveness against Severe Disease

    by Devendra Bansal, Jazeel Abdulmajeed, Maha H. M. A. Al-Shamali, Soha S. A. Albayat, Sayed M. Himatt, Farhan S. Cyprian, Tawanda Chivese, Jesha M. A. Mundodan, Hayat S. Khogali, Rekayahouda Baaboura, et al.

    Waning immunity following administration of mRNA-based COVID-19 vaccines remains a concern for many health systems. We undertook a study to determine if recent reports of waning for severe disease could have been attributed to design-related bias by conducting a study only among those detected with a first SARS-CoV-2 infection. We used a matched case-control study design with the study base being all individuals with first infection with SARS-CoV-2 reported in the State of Qatar between 1 January 2021 and 20 February 2022. Cases were those detected with first SARS-CoV-2 infection requiring intensive care (hard outcome), while controls were those detected with first SARS-CoV-2 infection who recovered without the need for intensive care. Cases and controls were matched in a 1:30 ratio for the calendar month of infection and the comorbidity category. Duration and magnitude of conditional vaccine effectiveness against requiring intensive care and the number needed to vaccinate (NNV) to prevent one more case of COVID-19 requiring intensive care was estimated for the mRNA (BNT162b2/mRNA-1273) vaccines. Conditional vaccine effectiveness against requiring intensive care was 59% (95% confidence interval (CI), 50 to 76) between the first and second dose, and strengthened to 89% (95% CI, 85 to 92) between the second dose and 4 months post the second dose in persons who received a primary course of the vaccine. There was no waning of vaccine effectiveness in the period from 4 to 6, 6 to 9, and 9 to 12 months after the second dose. This study demonstrates that, contrary to mainstream reports using hierarchical measures of effectiveness, conditional vaccine effectiveness against requiring intensive care remains robust till at least 12 months after the second dose of mRNA-based vaccines.


  • Open Access

    Demographics and Epidemiology of Hepatitis B in the State of Qatar: A Five-Year Surveillance-Based Incidence Study

    by Hamad E. Al Romaihi, Nandakumar Ganesan, Elmoubasher A. Farag, Maria K. Smatti, Gheyath K. Nasrallah, Sayed M. Himatt, Moutaz F. Derbala, Maha Alshamali, Lylu K. Mahadoon, Hayat S. Khogali, et al.

    Background: Expatriates represent >80% of Qatar’s population, mostly arriving from countries in Africa and Asia that are endemic with many diseases. This increases the risk for introducing new pathogens into the country and provides a platform for maintenance of endemic pathogen circulation. Here, we report on the incidence and epidemiological characteristics of hepatitis B in Qatar between 2010 and 2014. Methods: We performed a retrospective epidemiological data analysis using the data available at the surveillance system of the Ministry of Public Health (MOPH) in Qatar. Data were collected from distinctive public and private incorporates around the nation. Reported cases of hepatitis B patients represent those who met the stringent case definition as per World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC) guidelines and eventually reported to MOPH. Results: The annual incidence rates of hepatitis B cases were 30.0, 34.2, 30.5, 39.4, and 19.8 per 100,000 population in 2010, 2011, 2012, 2013, and 2014, respectively. There was no specific trend or seasonality for the reported cases. The incidence rates were higher in females compared to males between 2010 and 2012, but similar in 2013 and 2014. The highest incidence rates were reported among individuals between 25 and 34 years of age. No cases were reported in children younger than five years in 2013 and 2014. Rates of hepatitis B cases declined dramatically in 2014, in both Qataris and non-Qataris, as compared to the previous years. Conclusion: Our results indicate a dramatic decline of hepatitis B cases in Qatar but mandate improved surveillance and vaccination efforts in expatriates in the nation.